ProMIS Neurosciences gets additional 180-day Nasdaq compliance period for bid price deficiency until Dec 29, 2025

ProMIS Neurosciences Inc.

Nasdaq granted a second 180-day compliance period until December 29, 2025, to regain $1.00 minimum bid price.
Company may consider a reverse stock split or other actions to cure the deficiency.
If compliance not achieved by Dec 29, 2025, Nasdaq may delist Common Shares; no assurance of success.
Common shares continue trading on Nasdaq Capital Market under ticker PMN during this period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.